Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of doravirine + islatravir versus bictegravir + emtricitabine + tenofovir alafenamide in treatment-naive adults with HIV-1
2019-000590-23Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doravirine and islatravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of participants with HIV-1 RNA <50 copies/mL at Week 48. Started Dec 2019; status: active.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-000590-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000590-23.